search
Back to results

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

Primary Purpose

Hypoglycemia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Naltrexone High Dose
Naltrexone Low Dose
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypoglycemia focused on measuring Hypoglycemia, Type 1 diabetes

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk) age 18-55, BMI 18-35

Exclusion Criteria:

  • pregnancy
  • significant diabetes complications
  • liver disease, cirrhosis
  • cardiac disease
  • neurological disorder
  • autonomic neuropathy
  • kidney disease
  • lactose intolerance

Sites / Locations

  • Yale School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Naltrexone (higher dose)

Naltrexone (lower dose)

Arm Description

Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.

Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.

Outcomes

Primary Outcome Measures

Glucose (mg/dL)
Glucose was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Glucose Infusion Rate (mg/kg.Min)
The glucose infusion rate corresponds to the amount of 20% dextrose given during the hyperinsulinemic-hypoglycemic clamp study, necessary to keep blood glucose levels at the target range (50-55 mg/dL).

Secondary Outcome Measures

Glucagon (pg/mL)
Glucagon was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Cortisol (ug/dL)
Cortisol was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Epinephrine (pg/mL)
Epinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Norepinephrine (pg/mL)
Norepinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.

Full Information

First Posted
October 26, 2011
Last Updated
February 17, 2016
Sponsor
Yale University
Collaborators
National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT01462227
Brief Title
Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Official Title
The Effect of Opiate Blockade With Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
October 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institutes of Health (NIH)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels. However, this hormone response can be altered in people with diabetes. Currently there are no therapeutic agents that can be used to improve the recovery from hypoglycemia (low blood sugar). Naltrexone is a tablet used to help people who are addicted to alcohol or morphine-based drugs to remain drug and alcohol-free but it can also affect the levels of the hormones which are released during hypoglycemia. The aim of this study is to determine whether naltrexone can be used to improve and accelerate the recovery from hypoglycemia in patients with type 1 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoglycemia
Keywords
Hypoglycemia, Type 1 diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Naltrexone (higher dose)
Arm Type
Experimental
Arm Description
Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
Arm Title
Naltrexone (lower dose)
Arm Type
Experimental
Arm Description
Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
Intervention Type
Drug
Intervention Name(s)
Naltrexone High Dose
Intervention Description
Naltrexone 100mg for two administrations.
Intervention Type
Drug
Intervention Name(s)
Naltrexone Low Dose
Intervention Description
Naltrexone 50mg for two administrations.
Primary Outcome Measure Information:
Title
Glucose (mg/dL)
Description
Glucose was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Time Frame
End of study (up to 240 minutes)
Title
Glucose Infusion Rate (mg/kg.Min)
Description
The glucose infusion rate corresponds to the amount of 20% dextrose given during the hyperinsulinemic-hypoglycemic clamp study, necessary to keep blood glucose levels at the target range (50-55 mg/dL).
Time Frame
End of study (up to 240 minutes)
Secondary Outcome Measure Information:
Title
Glucagon (pg/mL)
Description
Glucagon was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Time Frame
End of study (up to 240 minutes)
Title
Cortisol (ug/dL)
Description
Cortisol was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Time Frame
End of study (up to 240 minutes)
Title
Epinephrine (pg/mL)
Description
Epinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Time Frame
End of study (up to 240 minutes)
Title
Norepinephrine (pg/mL)
Description
Norepinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.
Time Frame
End of study (up to 240 minutes)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk) age 18-55, BMI 18-35 Exclusion Criteria: pregnancy significant diabetes complications liver disease, cirrhosis cardiac disease neurological disorder autonomic neuropathy kidney disease lactose intolerance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Sherwin, MD
Organizational Affiliation
Yale School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

We'll reach out to this number within 24 hrs